Osteogenesis imperfecta in adults: Phenotypic characteristics and response to treatment in an Irish cohort

Irish Journal of Medical Science

Volumn 183, Issue 2, 2014, Pages 225-230

  O'Sullivan, E S ^a,b   Van Der Kamp, S ^a   Kilbane, M ^a   McKenna, M ^a,c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Bisphosphonates; Bone mineral density; Bone turnover markers; DXA; Fractures; NTx; Osteogenesis imperfecta; PINP; rhPTH

Indexed keywords

ADOLESCENT; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IRELAND; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE; PELVIC BONES; PHENOTYPE; RECOMBINANT PROTEINS; SPINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905189085     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-013-0995-x     Document Type: Article

References (24)

1. Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116 (Pubitemid 9164903)
2. Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540-557
3. Semler O, Garbes L, Keupp K et al (2012) A mutation in the 5′-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 91:349-357
4. Cho TJ, Lee KE, Lee SK et al (2012) A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 91:343-348
5. Baldridge D, Schwarze U, Morello R et al (2008) CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 29:1435-1442 (Pubitemid 352774897)
6. Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377-1385 (Pubitemid 38529880)
7. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM (2010) Classification of osteogenesis imperfecta revisited. Eur J Med Genet 53:1-5
8. Warman ML, Cormier-Daire V, Hall C et al (2010) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 155A:943-968
9. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363 (Pubitemid 17100571)
10. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24:1282-1289
11. Ward LM, Rauch F, Whyte MP et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355-364
12. Bishop N, Harrison R, Ahmed F et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25:32-40
13. Adami S, Gatti D, Colapietro F et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126-130 (Pubitemid 36008347)
14. Chevrel G, Schott AM, Fontanges E et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300-306 (Pubitemid 43265296)
15. Bradbury LA, Barlow S, Geoghegan F et al (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23:285-294
16. McKenna MJ, van der Kamp S, Au-Yeong M, FitzGerald O (2008) Improving standards of DXA. Ir Med J 101:101-102
17. Rauch F, Cornibert S, Cheung M, Glorieux FH (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821-827 (Pubitemid 46386546)
18. Land C, Rauch F, Glorieux FH (2006) Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21:374-379
19. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779-1786 (Pubitemid 41103428)
20. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121(475-83):e3
21. Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F (2012) Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab 30:434-438
22. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
23. Andrews EB, Gilsenan AW, Midkiff K et al (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429-2437
24. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)